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Abstract
Background: It has been debated whether treatment should be started early in subjects with mild to moderate
COPD. An impaired health status score was associated with a higher probability of being diagnosed with COPD as
compared with undiagnosed COPD.
Purpose: To investigate the health status in a healthy working population, to determine reference scores for
healthy non-smoking subjects, and to investigate the relationship between their health status and airflow limitation.
Methods: A total of 1333 healthy industrial workers aged ≥40 years performed spirometry and completed the
St. George’s Respiratory Questionnaire (SGRQ) and the COPD Assessment Test (CAT).
Results: The prevalence of COPD defined by the fixed ratio of the forced expiratory volume in one second
(FEV1)/forced vital capacity (FVC) was 10.9%, and the prevalence defined by the Lower Limit of Normal was 5.0%. All
SGRQ and CAT scores were skewed to the milder end. In 512 non-smoking subjects with normal spirometry, the
mean SGRQ score was 5.7, and the mean CAT score was 5.8. In 145 people with COPD defined by the fixed ratio, the
mean SGRQ score was 7.9, with a zero score in 6.9% of the subjects. Using the CAT, the mean score was 7.3, with
7.6% of the scores being zero. The scores in patients identified using the Lower Limit of Normal approach were:
SGRQ 8.4 (13.4% had a score of zero) and CAT 7.4 (13.4% had a score of zero). Although the 95th percentiles of the
Total, Symptoms, Activity, and Impact scores of the SGRQ and CAT sores were 13.8, 34.0, 23.4, 7.2 and 13.6 in the 512
healthy non-smoking subjects, respectively, they were also distributed under their upper limits in over 80% of the
COPD subjects.
Conclusion: The COPD-specific health status scores in a working population were good, even in those with
spirometrically diagnosed COPD. All scores were widely distributed in both healthy non-smoking subjects and in
subjects with COPD, and the score distribution overlapped remarkably between these two groups. This suggests that
symptom-based methods are not suitable screening tools in a healthy general population.
Keywords: Chronic obstructive pulmonary disease, St. George’s Respiratory Questionnaire, Symptoms and COPD,
Smoking and health, Health related quality of life
Background
It has been reported that chronic obstructive pulmon-
ary disease (COPD) remains under-diagnosed, with the
diagnosis being commonly missed or delayed until the
disease is advanced. Although some investigators have
proposed targeted, systematic case-identification as a
strategy to reduce the burden of COPD [1,2], others have
recommended that spirometry should not be used to
screen for airflow obstruction in asymptomatic individ-
uals, since little evidence exists to support the benefit of
interventions, except for smoking cessation, in early dis-
ease [3,4]. Furthermore, it has been debated whether
treatment should be started early in subjects with mild to
moderate COPD [5].
Several epidemiological studies have shown that only a
small proportion of subjects with COPD have had a prior
diagnosis, and that subjects with unrecognized COPD usu-
ally have mild to moderate airflow limitation [6-9]. Much
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less information is available about the health of patients
identified in this way. The Epidemiologic Study of COPD
in Spain (EPI-SCAN) found that 27% of identified COPD
cases had a previous diagnosis of COPD, and that an im-
paired health status score was associated with a higher
probability of being diagnosed with COPD as compared
with undiagnosed COPD [7].
We hypothesized that health status measurements may
identify undiagnosed subjects with mild to moderate
COPD. The purpose of the present study was to investi-
gate the health status in a healthy working population, to
determine reference scores for healthy non-smoking sub-
jects, and to investigate the relationship between their
health status and airflow limitation. The health status
was assessed by the St. George’s Respiratory Question-
naire (SGRQ) and the COPD Assessment Test (CAT™)
[10-12]. Two definitions of airflow limitation were used:
a fixed ratio of the FEV1/FVC < 0.7, and the Lower Limit
of Normal (LLN) definition [13,14].
Materials and methods
Subjects
The study was conducted between September 2010 and
March 2011 at the Niigata Association of Occupational
Health Incorporated, Niigata, Japan. The study subjects
were healthy industrial workers over forty years-old
who underwent annual health checks at this Associ-
ation. All had a comprehensive health screening, in-
cluding conventional spirometry, as well as a chest
radiograph. The exclusion criteria for this analysis in-
cluded: 1) abnormal findings of the pulmonary paren-
chyma and chest wall revealed on chest radiographs;
2) receiving a thoracotomy in the past; 3) any admis-
sion to a hospital during the preceding three months;
4) any physician-diagnosed pulmonary diseases including
lung cancer, pulmonary tuberculosis, bronchiectasis and
non-tuberculous mycobacteriosis; 5) a history of can-
cer or malignant disorders; and 6) unstable complications
of cardiovascular, neuromuscular, renal, endocrinological,
hematological, gastrointestinal, and hepatic co-morbidities.
Written informed consent was obtained from all partici-
pants. The present study was approved by the ethics
committee of the Niigata Association of Occupational
Health Incorporated.
In this study, COPD was spirometrically defined as
subjects with an airflow limitation of FEV1/FVC less
than a fixed ratio, 0.7, or a LLN without bronchodilator
administration. Healthy subjects were defined as a
FEV1 of >85% pred or a FEV1/FVC of >0.7, forming
two groups: subjects with a smoking history of ≥10
pack-yrs, and non-smoking subjects with a smoking
history of < 1 pack-yr. This definition was similar to that of
the Evaluation of COPD Longitudinally to Identify Predict-
ive Surrogate End-points (ECLIPSE) study [15].
Methods
All eligible subjects finished the following examinations
on the same day. Spirometry was performed with the
use of nose clips in the sitting position with a Spiro Sift
sp-470™ Spirometer (Fukuda Denshi Co., Ltd., Tokyo,
Japan). All measurements were performed by a labora-
tory technician (A.K.) in accordance with guidelines
published by the American Thoracic Society and the
European Respiratory Society [16]. The spirometric FVC
and FEV1 values were the largest FVC and largest FEV1
selected from data obtained from at least three accept-
able forced expiratory curves, even if these values were
not obtained from the same curve [17]. The predicted
values for pulmonary function were calculated based on
the proposal from the Japanese Respiratory Society [18].
The LLN for the Japanese population was calculated
using the method described by Osaka et al. [19]. The
Japanese versions of the SGRQ (version 2) and CAT
were administered under supervision prior to the pul-
monary function tests. These Japanese versions have
been previously validated [20,21]. The scores for three
components (Symptoms, Activity, and Impact) and the
Total score of the SGRQ were then calculated, as well as
the CAT score. The participants also answered add-
itional questions to investigate their smoking status and
history. Information about their radiographic findings
was obtained from annual health examinations.
Statistics
All results are expressed as means ± SD. Any missed
SGRQ items were handled according to the developers’
instructions in the SGRQ manual. A Mann–Whitney
U-test was used to compare the CAT and SGRQ scores
between two groups. A p value of less than 0.05 was con-
sidered to be statistically significant. Monte Carlo and
bootstrap methods with 1,000 bootstrap reps were used
to calculate the 95th percentile of the scores in healthy,
non-smoking subjects [22].
Results
A total of 1382 subjects participated at the beginning of
the present study. However, 49 subjects were excluded
from the data analysis because of uncertainty in their
smoking history or one of the exclusion criteria. There-
fore, a total of 1333 consecutive subjects (871 males)
were analysed. The average age of the subjects was
56.0 years. The mean FEV1/FVC ratio was 78.4%, range
40.2% to 94.4%. Their demographic details are shown in
Table 1.
Using the fixed ratio of the FEV1/FVC < 0.7, 145 sub-
jects were diagnosed with COPD, which included 140
out of 871 males (16.1%) and 5 out of 462 females
(1.1%). Using the Global Initiative for Chronic Obstruct-
ive Lung Disease (GOLD) criteria [23], 41.3% were in
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GOLD 1, 54.5% in GOLD 2 and 4.1% in GOLD 3 & 4,
(Table 1). Out of the 1188 subjects without COPD, there
were 512 nonsmoking subjects, 399 smoking subjects
and 277 others who smoked between 1 and 10 pack
years. Using the LLN definition, 67 subjects had COPD,
which included 64 males (7.3%) and 3 females (0.1%),
but 1266 were not considered to have COPD. The over-
all prevalence of COPD was 10.9% defined by the fixed
ratio, and 5.0% by the LLN. The greater prevalence in
males than in females was associated with the much
higher smoking rate in men.
The distributions of the Total score of the SGRQ and
the CAT score are shown in Table 2, and the three com-
ponents of the SGRQ are shown in Table 3. Since all of
the scores were skewed to the milder ends, a floor effect
was seen in all of the scores, most marked with the Impact
score of the SGRQ. The Total, Symptoms, and Impact
scores of the SGRQ were significantly different between
subjects with and without COPD as defined by the fixed
ratio (p = 0.040, <0.001 and 0.001, respectively, Mann–
Whitney U-test), but the SGRQ Activity score and the
CAT score were not different between the two groups. The
SGRQ Symptoms and Impact scores were significantly
higher in subjects with COPD as defined by the LLN than
in subjects without COPD (both p < 0.001), but the SGRQ
Total and Activity scores and the CAT score were not sig-
nificantly different between the two groups.
As a secondary endpoint, it was an objective to deter-
mine reference values for each score. Therefore, we cal-
culated the 95th percentile of the scores in 512 healthy,
non-smoking subjects using the Monte Carlo method and
used this as the upper limit of normal. For the SGRQ, these







Prior diagnosis FEV1 FEV1/FVC
Number (%)
number Years number (%) pack-years number (%) Asthma COPD % pred %
All subjects 1333 56.0 ± 8.2 871 (65.3%) 17.0 ± 21.7 556 (41.7%) 21 (1.6%) 7 (0.5%) 95.8 ± 14.8 78.4 ± 6.7
Non-COPD defined by fixed ratio 1188 55.4 ± 8.1 731 (61.5%) 14.3 ± 19.3 539 (45.4%) 18 (1.5%) 0 (0%) 98.2 ± 13.0 80.1 ± 4.5
COPD defined by fixed ratio 145 61.0 ± 7.7 140 (96.6%) 38.4 ± 27.5 17 (11.7%) 3 (2.1%) 7 (4.8%) 76.6 ± 15.1 64.6 ± 5.6
Non-COPD defined by LLN 1266 55.7 ± 8.2 807 (63.7%) 15.6 ± 20.1 548 (43.3%) 19 (1.5%) 1 (0.1%) 97.3 ± 13.5 79.4 ± 5.2
COPD defined by LLN 67 60.6 ± 7.2 64 (95.5%) 43.0 ± 32.5 8 (11.9%) 2 (3.0%) 6 (8.9%) 68.8 ± 13.0 60.3 ± 5.7
Healthy non-smoking subjects¶# 512 56.2 ± 8.2 123 (24%) 0.0 ± 0.1 495 (96.7%) 8 (1.6%) 0 (0%) 104.5 ± 11.3 81.4 ± 4.4
Healthy smoking subjects¶* 399 54.7 ± 8.0 373 (93.5%) 29.1 ± 15.9 0 (0%) 6 (1.5%) 0 (0%) 98.0 ± 9.0 79.7 ± 4.1
COPD/GOLD stageI 60 60.8 ± 7.5 57 (95.0%) 33.4 ± 23.3 10 (16.7%) 1 (1.7%) 0 (0%) 90.4 ± 8.8 67.4 ± 2.6
COPD/GOLD stageII 79 61.4 ± 8.0 78 (98.7%) 42.1 ± 30.2 6 (7.6%) 1 (1.3%) 7 (8.9%) 68.6 ± 7.7 63.6 ± 4.8
¶ FEV1 of >85% pred and FEV1/FVC of >0.7, # smoking history of < 1 pack-yr, * smoking history of ≥10 pack-yrs.
Table 2 Score distribution of the Total score of the SGRQ and CAT scores
SGRQ Total (0–100) CAT (0–40)
Mean Median SD Max Floor effect Mean Median SD Max Floor effect
All subjects 6.4 5.3 5.7 51.5 8.9% 6.4 6.0 4.6 26.0 7.4%
Non-COPD defined by fixed ratio 6.31) 5.3 5.4 43.2 9.1% 6.3 6.0 4.5 24.0 7.3%
COPD defined by fixed ratio 7.9 6.4 7.6 51.5 6.9% 7.3 6.0 5.2 26.0 7.6%
Non-COPD defined by LLN 6.3 5.3 5.6 51.5 8.6% 6.4 6.0 4.5 24.0 7.0%
COPD defined by LLN 8.4 6.7 7.5 34.0 13.4% 7.4 6.0 5.9 26.0 13.4%
Healthy non-smoking subjects¶# 5.72)3)4)5) 4.9 4.9 43.2 10.5% 5.82)3)4) 5.0 4.4 23.0 9.4%
Healthy smoking subjects¶* 6.8 5.8 5.5 37.1 7.5% 6.8 6.0 4.4 24.0 5.3%
COPD/GOLD stageI 8.1 5.7 9.2 51.5 5.0% 7.2 6.0 5.1 21.0 6.7%
COPD/GOLD stageII 7.5 6.4 6.1 26.8 8.9% 7.2 6.0 5.3 26.0 8.9%
¶ FEV1 of >85% pred and FEV1/FVC of >0.7, # smoking history of <1 pack-yr, * smoking history of ≥10 pack-yrs.
1) p < 0.05 compared with COPD defined by fixed ratio.
2) p < 0.01 compared with healthy smoking subjects.
3) p < 0.01 compared with COPD defined by fixed ratio.
4) p < 0.05 compared with COPD/GOLD stageII.
5) p < 0.05 compared with COPD defined by LLN.
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values were a SGRQ Total score 13.8, Symptoms score
34.0, Activity score 23.4, and Impact score 7.2; for the
CAT, it was 13.6 (which rounds to 14, since the CAT
score does not contain decimals). In the subjects with
COPD, over 80% of the SGRQ and CAT scores fell
below these values. The median SGRQ Symptoms score
in the healthy subjects was 11.0, and in those subjects
diagnosed with COPD using the fixed ratio, 24.1% had
scores less than this. Thus, the score distributions
overlapped widely between healthy, non-smoking sub-
jects and those identified by spirometry, regardless of
the definition used (Figures 1 and 2).
Discussion
This study showed that the health status scores of un-
diagnosed COPD patients in a working population were
very close to the scores in subjects without COPD from
the same study population, regardless of the health status
score used or the spirometric method used to diagnose
COPD. This supports a previous observation that people
with undiagnosed COPD and identified on spirometric
screening have better SGRQ scores than those previously
diagnosed [7]. Three main conclusions may be drawn
from this. First, undiagnosed people with COPD who are
in paid employment have a well preserved health status.
Second, in such populations, symptom-based screening
tools are unlikely to identify undiagnosed patients, or act
as case-finding tools. Third, setting aside smoking cessa-
tion (which ought to be a universal health care aim) and
the identification of patients with a high frequency of
exacerbations but minimal symptoms (Group C using
the GOLD 2011 classification) [23], this study lends little
support to screening studies in healthy populations.
The participants in this study were healthy industrial
workers over 40 years-old in Japan. The prevalence of
COPD defined by the fixed ratio was 10.9%, whereas that
defined by the LLN was 5.0%. Although there have been
only a few population-based surveys regarding the preva-
lence of COPD in Japan, these figures are very similar to
Table 3 Score distribution of the three components of the SGRQ
SGRQ Symptoms (0–100) SGRQ Activity (0–100) SGRQ Impact (0–100)
Mean Median SD Max Floor
effect
Mean Median SD Max Floor
effect
Mean Median SD Max Floor
effect
All subjects 15.8 13.5 14.0 81.8 19.1% 9.1 6.0 9.1 59.5 34.0% 1.8 0.0 4.9 47.2 77.8%
Non-COPD defined by fixed ratio 15.01)2)3) 12.9 13.5 74.0 20.1% 9.1 6.0 8.9 59.5 33.3% 1.71)3) 0.0 4.7 44.3 79.0%
COPD defined by fixed ratio 21.7 18.8 16.3 81.8 10.3% 9.3 6.0 10.9 48.9 39.3% 2.7 0.0 6.0 47.2 67.6%
Non-COPD defined by LLN 15.44) 12.9 13.7 81.8 19.1% 9.1 6.0 8.9 59.5 33.4% 1.74) 0.0 4.8 47.2 78.8%
COPD defined by LLN 22.0 18.8 16.5 76.3 17.9% 9.5 6.0 11.9 43.0 44.8% 3.4 0.0 5.6 26.6 59.7%
Healthy non-smoking subjects¶# 12.51)2)3)4) 11.0 11.7 74.0 23.8% 8.9 6.2 9.0 59.5 36.1% 1.41)3)4)8) 0.0 4.7 44.3 82.2%
Healthy smoking subjects¶* 17.31)4)7) 15.4 14.0 72.2 16.0% 9.1 6.0 8.3 45.5 28.8% 1.94)9) 0.0 5.0 36.3 75.9%
COPD/GOLD stageI 21.9 20.3 17.6 81.8 6.7% 9.2 6.0 11.3 48.9 38.3% 3.1 0.0 7.9 47.2 73.3%
COPD/GOLD stageII 21.3 18.7 15.8 76.3 13.9% 8.8 6.0 10.1 43.0 40.5% 2.3 0.0 4.2 18.1 67.1%
¶ FEV1 of >85% pred and FEV1/FVC of >0.7, # a smoking history of <1 pack-yr, * a smoking history of ≥10 pack-yrs.
1) p < 0.01 compared with COPD defined by fixed ratio.
2) p < 0.01 compared with COPD/GOLD stageI.
3) p < 0.01 compared with COPD/GOLD stageII.
4) p < 0.01 compared with COPD defined by LLN.
5) p < 0.01 compared with healthy smoking subjects.
6) p < 0.05 compared with COPD/GOLD stageII.
7) p < 0.05 compared with COPD defined by LLN.
8) p < 0.05 compared with healthy smoking subjects.
9) p < 0.05 compared with COPD defined by fixed ratio.
Figure 1 Box plots representing the score distributions of
the SGRQ Total score in healthy non-smoking subjects,
COPD defined by the fixed ratio and COPD defined by the
LLN. * p < 0.01, †p < 0.05; both significant differences in the
scores were observed for healthy non-smoking subjects.
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those reported in the Nippon COPD Epidemiology
(NICE), in which the prevalence defined by the fixed ra-
tio was 10.9% [6]. Similarly, in a community-based an-
nual health check, Osaka et al. also reported that 10.6%
had COPD as defined by the fixed ratio and 6.4% had
COPD as defined by the LLN [19]. Thus, the prevalence
of COPD is similar to previous studies in Japan.
Although many population-based surveys using spir-
ometry have reported the under-diagnosis of COPD, this
frequency is highly variable. Analyses of population-
based data from the US suggest that 63.3% had no prior
or current reported diagnosis of any obstructive lung dis-
ease [24]. This percentage ranges from 19 to 27% in
European studies, but is the lowest in Latin America
(11.3%) and in Japan (9.4%) [6,25]. Therefore, the small
number of subjects in our study with a prior diagnosis of
COPD may also be related to their national background.
To the best of our knowledge, there has been no defin-
ition of “asymptomatic” COPD. A simple answer to the
choice of yes or no for a single question may not be reli-
able or valid to determine the presence of symptoms.
Nonetheless, a reproducible and quantitative measure-
ment of symptoms is necessary. Since symptoms are one
of the essential components of health status, some sub-
jective markers obtained from established methods of
patient-reported outcomes could be candidates. It is rea-
sonable to argue that subjects with a floor effect (zero
score) on their scores obtained from disease-specific in-
struments are asymptomatic for that disease. In our
study, approximately 7% of the subjects with COPD had
zero scores whether using the SGRQ Total score or the
CAT, and hence we conclude that only a small number
of subjects with undiagnosed COPD are free of any
symptoms. Nonetheless, people with asymptomatic COPD
may have some problems with their health, for example
comorbidity.
Although the Total score of the SGRQ and the CAT
score were significantly better in healthy, non-smoking
subjects than in subjects with COPD, the difference in
the scores is very small, and the score distributions were
also similar. All of the scores were widely distributed in
both groups, and the score distribution overlapped to a
large extent between the two groups. Although we have
created reference values for healthy, non-smoking sub-
jects, it became apparent that they are not useful to
identify undiagnosed people with COPD.
Ohar et al. studied 3955 subjects using work-related
medical evaluations, and observed that respiratory symp-
toms were reported by 92% of smokers with airflow limi-
tation, 76% of smokers with normal spirometry, and 73%
of non-smokers, and concluded that the high prevalence
of symptoms resulted in a poor predictive value for
COPD [26]. However, they examined symptoms using a
simple binary choice of yes or no during face-to-face in-
terviews. Although it is difficult to directly compare their
results with ours due to the differences in methodology,
their conclusion is similar to ours. In the ECLIPSE study,
Agusti et al. reported SGRQ scores of 9.6 in non-COPD
smokers and 4.5 in non-smoking controls. These esti-
mates are also quite similar to ours. However, the scores
in their patients (diagnosed with COPD and under hos-
pital outpatient treatment) were much higher, with a
mean of 50.1 [27]. This large difference between the
studies is compatible with the observation that SGRQ
scores in undiagnosed COPD patients identified by spi-
rometric screening were considerably better than pa-
tients with a prior diagnosis of COPD [7]. The clear
inference to be drawn is that COPD patients are diag-
nosed because of many noticeable symptoms, and it is
reasonable to draw the opposite conclusion, that many
of those who are not diagnosed have fewer symptoms.
This means that in a general population, the use of
symptomatic instruments may not be a sensitive method
of identifying people who should undergo spirometric
testing. This conclusion is supported by a report from
Salameh et al. that the Diagnosis Score for COPD (DS-
COPD) differentiated between COPD and other individ-
uals with respiratory symptoms, but had no utility in
identifying asymptomatic individuals [28].
Some limitations of the present study should be men-
tioned. Since the study subjects were not randomly sam-
pled, there was a risk of sample bias. For example,
healthy people may have been more likely to volunteer,
although people with some symptoms may have also
taken the opportunity to have a more thorough ‘check-
up’. The study was limited by a relatively small number
of participants; however, it is clear from the distribution
Figure 2 Box plots representing the score distributions of the
CAT score in healthy non-smoking subjects, COPD defined by
the fixed ratio and COPD defined by the LLN. * p < 0.01;
significant differences in the scores were observed for healthy
non-smoking subjects.
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in the SGRQ and CAT scores, that a great number of
participants would have increased the precision of the
mean estimates, but would not have materially altered
the overall findings. In addition, GOLD defines airflow
limitation as a post-bronchodilator FEV1/FVC < 0.70.
However, this study did not evaluate post-bronchodilator
values. Although the diagnosis of COPD may require
somewhat more than only spirometry in clinical practice,
the diagnosis was made only from spirometric information
in the present study. The SGRQ and CAT are valid instru-
ments for measuring health status in patients with diag-
nosed COPD, but most of the participants in our study
were not patients with known COPD but rather healthy
workers, and thus the SGRQ and CAT may have been in-
appropriate questionnaires for this study population. That
having been said, most patients had scores that were not
zero, indicating that most participants felt that some of the
items did reflect their health state, even though they did
not have a COPD diagnosis.
Conclusion
Although the health status scores were statistically signifi-
cantly different between healthy non-smoking subjects and
those with COPD, the scores were widely distributed in
both groups, and the score distribution overlapped widely.
In a working population, a low level of respiratory-related
symptom may be present in many subjects without airflow
limitation, but there are also some apparently asymptom-
atic people with COPD (as judged by the SGRQ and CAT).
We conclude that most working people who do meet the
spirometric criteria for COPD are likely to have a well-
preserved health status.
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